As per MRFR analysis, the India Glioblastoma Market Size was estimated at 141.24 (USD Million) in 2023. The India Glioblastoma Market Industry is expected to grow from 149.46(USD Million) in 2024 to 712.6 (USD Million) by 2035. The India Glioblastoma Market CAGR (growth rate) is expected to be around 15.257% during the forecast period (2025 - 2035).
The India Glioblastoma Market is witnessing several important trends driven by rising awareness and advancements in healthcare. Increased funding for cancer research and the efforts of various government initiatives aim to improve diagnosis and treatment options for glioblastoma. The Indian government has been prioritizing cancer treatment through schemes such as the Ayushman Bharat, which provides health coverage to a significant portion of the population, thereby enhancing access to necessary therapies. There is also a growing adoption of advanced technologies, such as precision medicine and targeted therapies, which offer better outcomes for patients with glioblastoma.This market still has opportunities to improve already existing methods of early diagnosis and treatment.
The Indian pharmaceutical industry is increasingly shifting its focus towards the development of targeted therapies in the form of generic drugs and biosimilars, thus enhancing the affordability and accessibility of glioblastoma treatment. Partnerships between biotech companies and research organizations are also on the rise, which helps in fueling innovation and creating new therapies. There is also a notable increase in the attention given to clinical trials focused on developing novel therapies for glioblastoma, indicating a growing trend toward personalized medicine.
Additionally, rising partnerships between private and public sectors in India are pushing the agenda for better cancer care. The participation of patient advocacy groups in awareness campaigns is creating a more informed patient population, which could lead to earlier diagnosis and treatment intervention. These trends highlight a focused effort to address glioblastoma effectively, underscoring both the challenges and advancements within the Indian healthcare landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The India Glioblastoma Market Industry is experiencing growth due to the alarming rise in the incidence of glioblastoma. According to the National Cancer Registry Programme of India, there has been a substantial increase in brain tumor cases, with an estimate of over 30,000 new cases each year. This surge correlates with a broader increase in cancer cases overall, with female cancer patients in India rising by 4.7% and male cancer patients by 3.8% over the last decade.Organizations like the Indian Council of Medical Research are focusing on cancer research, leading to improved diagnosis and treatment options for glioblastoma. As awareness and detection improve, more cases are being identified, driving the market for novel therapies and treatment protocols aimed at glioblastoma management.
Technological advancements and the introduction of innovative treatment options are vital drivers for the India Glioblastoma Market Industry. The integration of technologies like personalized medicine and immunotherapy is gaining traction, with the Cancer Genome Atlas reporting that targeted therapies improve survival rates significantly. As pharmaceutical companies invest in Research and Development (R&D) for glioblastoma treatments, the number of clinical trials has surged, presenting new opportunities for patients.With increasing support from organizations like the Department of Biotechnology, these advancements are projected to enhance treatment efficacy, thereby expanding the market scope.
Government initiatives aimed at cancer control are significantly influencing the India Glioblastoma Market Industry. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke seeks to reduce the cancer burden through increased funding and awareness campaigns. Reports indicate a projected allocation of significant funds by the Government of India towards cancer research and healthcare infrastructure, which is expected to facilitate early detection and increased access to advanced treatment options for glioblastoma patients.Such strategic investments are likely to bolster growth in the market as more patients receive timely and effective care.
The India Glioblastoma Market, particularly under the Treatment Type segment, showcases a diverse range of therapeutic interventions aimed at tackling this aggressive form of brain cancer. The market is characterized by a comprehensive approach that includes Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy. Surgery, often considered the first line of defense, plays a pivotal role as it aims to remove as much of the tumor as possible, leading to improved patient outcomes and often serving as a critical factor for subsequent treatments. Radiation Therapy utilized post-surgery, leverages high-energy particles to destroy remaining cancerous cells and is crucial in managing local disease control, particularly given the aggressive nature of glioblastoma. Chemotherapy, which employs potent drugs to target rapidly dividing cells, often works alongside surgeries and radiation to enhance the likelihood of treatment success, providing a systemic approach to combat potential metastasis.
In recent years, Targeted Therapy has emerged as a significant player in the treatment landscape, focusing on specific genetic and molecular markers associated with glioblastoma, which allows for more personalized treatment regimens and better management of side effects. Immunotherapy represents a progressive trend within the market, harnessing the body's immune system to identify and destroy cancer cells, bringing promising results and a new hope for patients who have limited options after conventional therapeutic strategies fail. The increasing prevalence of glioblastoma in India emphasizes the need for a diversified treatment approach, combining these therapies to maximize patient outcomes.
Additionally, advancements in technology and Research and Development initiatives have resulted in innovative treatment options gaining traction in the market. The potential for these treatment modalities to evolve with ongoing clinical trials and the incorporation of new findings will continue to shape India's Glioblastoma Market. As the healthcare system in India adopts more advanced and holistic treatment methodologies, a comprehensive understanding of these treatment types becomes vital for stakeholders aiming to improve patient care and outcomes within the realm of glioblastoma treatment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Drug Type segment within the India Glioblastoma Market presents a diverse landscape, reflecting the complexities of treatment options available for this aggressive form of brain cancer. Temozolomide has established itself as a cornerstone in glioblastoma management due to its oral administration and effectiveness as a chemotherapeutic agent. Bevacizumab, known for its anti-angiogenic properties, plays a crucial role by targeting the tumor's blood supply, thus enhancing patient outcomes. Carmustine remains significant in clinical settings, often utilized in conjunction with other therapies to maximize efficacy.
Nivolumab, an immunotherapy agent, is gaining traction for its potential to activate the body’s immune response against cancer cells. Lomustine also contributes meaningfully, often seen in combination regimens, offering versatility in treatment protocols. The growth of these therapeutic options in India is driven by increasing incidences of glioblastoma, improved healthcare infrastructure, and greater awareness of treatment advancements. Each drug brings distinct mechanisms of action and benefits, contributing to the overall efforts against glioblastoma and underscoring the importance of ongoing Research and Development within this market segment.As the India Glioblastoma Market evolves, these drug types will be pivotal in addressing the unmet needs of patients and healthcare providers alike.
The Distribution Channel for the India Glioblastoma Market plays a crucial role in ensuring access to essential treatments for patients dealing with this aggressive form of brain cancer. The primary channels include Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Specialty Pharmacy, each serving its unique purpose in the healthcare ecosystem. Hospital pharmacies typically dominate the market as they cater to inpatients requiring immediate access to medications, making them vital in treatment frameworks. Retail pharmacies also serve a significant number of outpatients, providing easy access to necessary medications in communities throughout India.The rise of online pharmacies has revolutionized the market by offering convenience and the ability for patients to obtain medications discreetly, especially in urban areas where internet penetration is high. Specialty pharmacies are particularly noteworthy due to their focus on high-cost, complex drugs that require special handling and administration, reflecting the growing need for specialized treatment pathways in the Indian healthcare landscape. Overall, the diverse distribution channels highlight the adaptability and responsiveness of the healthcare sector in India to meet the increasing demand for glioblastoma treatments.
The End User segment of the India Glioblastoma Market plays a crucial role in addressing the healthcare needs of patients diagnosed with this aggressive form of brain cancer. Hospitals are significant contributors, providing specialized care, advanced surgical interventions, and comprehensive treatment options, which is essential in a country like India, where healthcare infrastructure is continually evolving. Clinical Research Organizations serve as key players in conducting vital clinical trials and research, thus driving innovation in treatment modalities and therapeutic approaches for glioblastoma.Homecare settings have gained importance as they offer personalized care and comfort to patients, facilitating access to therapy in a familiar environment. This trend aligns with the growing emphasis on patient-centric care within India’s healthcare framework. The rising number of glioblastoma cases, coupled with increasing awareness and research breakthroughs, strengthens the demand across these end-user categories, leading to a dynamic transformation in how glioblastoma is treated and managed in India. Market growth in these segments reflects broader trends in the healthcare system, driven by an aging population and increasing accessibility to healthcare facilities.
The India Glioblastoma Market is characterized by a complex landscape where several pharmaceutical players are vying for dominance in the drug development and treatment space. This market has gained significant traction due to the increasing prevalence of glioblastoma, a severe form of brain cancer. Rising awareness about advanced treatment options and ongoing clinical trials further contribute to the competitive intensity within this sector. The market is defined not only by traditional treatment methods like surgery and radiotherapy but also by innovative therapies that target the underlying biology of the disease. As research yields new insights into glioblastoma, companies are compelled to adapt their strategies, invest in research and development, and forge partnerships to enhance their market presence.Celgene has established a solid reputation within the India Glioblastoma Market, leveraging its significant strengths in research and development to create impactful therapeutic solutions.
The company focuses on fostering innovative therapies that cater specifically to the needs of glioblastoma patients. Its commitment to advancing treatment options, coupled with extensive collaborations with various research institutions, enables Celgene to stay at the forefront of scientific discovery. In India, Celgene has built strong relationships with healthcare providers and oncologists, which enhances its ability to deliver effective solutions tailored to the local market demands. The company’s proactive involvement in clinical trials and patient advocacy initiatives has further bolstered its position, allowing it to critically evaluate and optimize treatment approaches based on evolving patient needs.Novartis also plays a crucial role in the India Glioblastoma Market, recognized for its comprehensive portfolio of innovative therapies targeting cancer treatment.
The company offers key products that are pivotal in managing glioblastoma and has a solid market presence stemming from its strategic focus on oncology. Novartis has consistently emphasized the importance of research, yielding novel treatments that aim to improve patient outcomes. The company has engaged in strategic mergers and acquisitions that enhance its capacity for developing breakthrough therapies, thereby strengthening its foothold in the competitive landscape. In India, Novartis draws on its extensive network and partnerships with healthcare professionals to ensure that its cutting-edge therapies are accessible to patients. This focus on collaboration, combined with its commitment to patient-centric solutions, positions Novartis as a formidable entity in the glioblastoma market, navigating challenges while contributing to advancements in cancer care.
The India Glioblastoma Market has recently experienced notable developments, particularly with regard to advancements in treatment options. Companies like Novartis and Merck and Co. have been focusing on innovative therapies, including targeted treatments, which have garnered increased interest from the healthcare community. In August 2023, Bristol-Myers Squibb expanded its glioblastoma program, aiming to investigate new immunotherapy combinations, which has further enhanced its presence in the market. Furthermore, significant mergers are reshaping the landscape; for instance, Eli Lilly announced its strategic acquisition of a biotech firm in July 2023 to bolster its oncology pipeline, aiming to develop more effective glioblastoma treatments. The market valuation has been positively influenced by these developments as investment in Research and Development continues to rise. Over the past two years, the Indian government has also ramped up funding for cancer research initiatives, demonstrating its commitment to addressing high-incidence cancers like glioblastoma through both public and private sector partnerships. With companies like Pfizer and Roche focusing on collaborative clinical trials, the market is expected to see further innovations and advancements aimed at improving patient outcomes in India.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 141.24(USD Million) |
| MARKET SIZE 2024 | 149.46(USD Million) |
| MARKET SIZE 2035 | 712.6(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.257% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Celgene, Novartis, AstraZeneca, Merck and Co., Eli Lilly, BristolMyers Squibb, Sandoz, Beckman Coulter, Pfizer, Amgen, Roche, AbbVie, GSK, Mylan, Bayer |
| SEGMENTS COVERED | Treatment Type, Drug Type, Distribution Channel, End User |
| KEY MARKET OPPORTUNITIES | Increased investment in R&D, Growing demand for targeted therapies, Expansion of diagnostic technologies, Rising incidence of glioblastoma, Strategic collaborations and partnerships |
| KEY MARKET DYNAMICS | increasing incidence rates, rising awareness initiatives, advancements in treatment options, government funding support, growing diagnostic technologies |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Glioblastoma Market is expected to be valued at 149.46 million USD in 2024.
By 2035, the market is anticipated to reach a value of 712.6 million USD.
The market is projected to grow at a CAGR of 15.257% from 2025 to 2035.
Surgery is expected to hold the largest market share, valued at 40.0 million USD in 2024.
Radiation Therapy is valued at approximately 30.0 million USD in 2024.
Chemotherapy is projected to reach a market value of 220.0 million USD by 2035.
Key players include Celgene, Novartis, AstraZeneca, Merck & Co., Eli Lilly, and others.
Immunotherapy is expected to be valued at 62.6 million USD by 2035.
The market for Targeted Therapy is projected to grow from 20.0 million USD in 2024 to 100.0 million USD in 2035.
The market faces challenges related to high treatment costs and complex regulatory frameworks.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
